 VANCOUVER and MINNEAPOLIS, May 10, 2021 GLOBE NEWSWIRE -- via NewMediaWire Neovasc Inc. Neovasc or the Company NASDAQ, TSX: NVCN today announced that the first patient has been enrolled in the COronary SInus Reducer for the Treatment of Refractory Microvascular Angina COSIMA trial. The enrollment occurred at University Hospital, Mainz, Germany. The patient is an 82-year-old woman who suffers from severe Canadian Cardiovascular Society CCS Class IV angina on a daily basis despite optimal medical treatment. The study is being led by Prof. Tommaso Gori, M.D., Ph.D., University Medical Center, Mainz, Germany. 